{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T15:50:59Z","timestamp":1791906659144,"version":"4.3.4"},"reference-count":108,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T00:00:00Z","timestamp":1751932800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>Rilpivirine (RPV, R278474) was highlighted in 2005, two years after the death of Dr. Paul Janssen, as the ideal non-nucleoside reverse transcriptase inhibitor (NNRTI) to treat HIV infections. For this purpose, it was subsequently combined with tenofovir disoproxil fumarate (TDF), tenofovir alafenamide (TAF), darunavir (boosted with ritonavir or cobicistat) or dolutegravir. Its wide-spread use is thanks to its combination with cabotegravir (CAB) in the form of a long-acting intramuscular injection once per month (QM), later twice per month (Q2M), for the treatment of adults, later extended to adolescents and pregnant women, with HIV infections. The long-acting CAB plus RPV should not be administered in patients treated with rifampicin or rifabutin, patients with virological failure or patients with resistance to CAB or RPV, or patients with hepatitis B virus (HBV) infection. Long-acting CAB+RPV may lead to pain at the site of injection which would diminish over time.<\/jats:p>","DOI":"10.3390\/v17070959","type":"journal-article","created":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T09:12:48Z","timestamp":1751965968000},"page":"959","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["The Meandrous Route of Rilpivirine in the Search for the Miraculous Drug to Treat HIV Infections"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2985-8890","authenticated-orcid":false,"given":"Erik","family":"De Clercq","sequence":"first","affiliation":[{"name":"Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, KU Leuven, B-3000 Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,7,8]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1021\/jm040840e","article-title":"In search of a novel anti-HIV drug: Multidisciplinary coordination in the discovery of 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile (R278474, rilpivirine)","volume":"48","author":"Janssen","year":"2005","journal-title":"J. Med. Chem."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1038\/343470a0","article-title":"Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives","volume":"343","author":"Pauwels","year":"1990","journal-title":"Nature"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1021\/jm030558s","article-title":"Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants","volume":"47","author":"Das","year":"2004","journal-title":"J. Med. Chem."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"4680","DOI":"10.1128\/AAC.48.12.4680-4686.2004","article-title":"TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1","volume":"48","author":"Andries","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"12773","DOI":"10.1128\/JVI.79.20.12773-12782.2005","article-title":"TMC125 displays a high genetic barrier to the development of resistance: Evidence from in vitro selection experiments","volume":"79","author":"Vingerhoets","year":"2005","journal-title":"J. Virol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.coph.2004.07.005","article-title":"New non-nucleoside reverse transcriptase inhibitors (NNRTIs) in development for the treatment of HIV infections","volume":"4","author":"Pauwels","year":"2004","journal-title":"Curr. Opin. Pharmacol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1021\/jm040838n","article-title":"Synthesis of novel diarylpyrimidine analogues and their antiviral activity against human immunodeficiency virus type 1","volume":"48","author":"Guillemont","year":"2005","journal-title":"J. Med. Chem."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Zhang, T., Yang, J., Zhou, Z., Fu, Z., Cherukupalli, S., Kang, D., Zhan, P., and Liu, X. (2021). The development of an effective synthetic route of rilpivirine. BMC Chem., 15.","DOI":"10.1186\/s13065-021-00749-y"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e2201067","DOI":"10.1002\/jssc.202201067","article-title":"Simultaneous quantification of (E) and (Z) isomers of rilpivirine and four degradation products in bulk and tablets by reversed-phase ultra-high-performance liquid chromatography and confirmation of all by molecular weight","volume":"46","author":"Mhaske","year":"2023","journal-title":"J. Sep. Sci."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s12981-019-0222-6","article-title":"Efficacy and improvement of lipid profile after switching to rilpivirine in resource limited setting: Real life clinical practice","volume":"16","author":"Gatechompol","year":"2019","journal-title":"AIDS Res. Ther."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1128\/AAC.00986-09","article-title":"TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1","volume":"54","author":"Azijn","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1038\/clpt.2014.118","article-title":"A compartmental pharmacokinetic evaluation of long-acting rilpivirine in HIV-negative volunteers for pre-exposure prophylaxis","volume":"96","author":"Jackson","year":"2014","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e569","DOI":"10.1016\/S2352-3018(16)30113-8","article-title":"Long-acting rilpivirine as potential pre-exposure prophylaxis for HIV-1 prevention (the MWRI-01 study): An open-label, phase 1, compartmental, pharmacokinetic and pharmacodynamic assessment","volume":"3","author":"McGowan","year":"2016","journal-title":"Lancet HIV"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1089\/aid.2018.0265","article-title":"A multiple dose phase 1 assessment of rilpivirine long acting in a model of preexposure prophylaxis against HIV","volume":"35","author":"Cranston","year":"2019","journal-title":"AIDS Res. Hum. Retroviruses"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1089\/aid.2020.0155","article-title":"Metabolism of long-acting rilpivirine after intramuscular injection: HIV prevention trials network study 076 (HPTN 076)","volume":"37","author":"Seneviratne","year":"2021","journal-title":"AIDS Res. Hum. Retroviruses"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"393","DOI":"10.3851\/IMP3331","article-title":"Prevalence of pretreatment and acquired HIV-1 mutations associated with resistance to lamivudine or rilpivirine: A systematic review","volume":"24","author":"Vannappagari","year":"2019","journal-title":"Antivir. Ther."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1089\/aid.2022.0065","article-title":"Dynamics of rilpivirine resistance-associated mutation: E138 in reverse transcriptase among antiretroviral-naive HIV-1-infected individuals in Turkey","volume":"39","author":"Sayan","year":"2023","journal-title":"AIDS Res. Hum. Retroviruses"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1093\/jac\/dkaa017","article-title":"Rilpivirine in HIV-1-positive women initiating pregnancy: To switch or not to switch?","volume":"75","author":"Frange","year":"2020","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Islam, S., Rahaman, M.H., Yu, M., Noll, B., Martin, J.H., Wang, S., and Head, R. (2023). Anti-leukaemic activity of rilpivirine Is mediated by Aurora A kinase inhibition. Cancers, 15.","DOI":"10.3390\/cancers15041044"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Pereira, M., and Vale, N. (2023). Evolution of antiretroviral drug rilpivirine and approach to oncology. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24032890"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1136\/gutjnl-2019-318372","article-title":"Rilpivirine attenuates liver fibrosis through selective STAT1-mediated apoptosis in hepatic stellate cells","volume":"69","author":"Alegre","year":"2020","journal-title":"Gut"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1016\/j.ymthe.2019.10.006","article-title":"Suppression of Zika virus infection in the brain by the antiretroviral drug rilpivirine","volume":"27","author":"Sariyer","year":"2019","journal-title":"Mol. Ther."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1080\/17512433.2019.1608523","article-title":"Effect of rilpivirine on the pharmacokinetics of methadone in HIV-Infected Chinese patients","volume":"12","author":"Lei","year":"2019","journal-title":"Expert. Rev. Clin. Pharmacol."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Gra\u00f1ana-Castillo, S., Montanha, M.C., Bearon, R., Khoo, S., and Siccardi, M. (2022). Evaluation of drug-drug interaction between rilpivirine and rifapentine using PBPK modelling. Front. Pharmacol., 13.","DOI":"10.3389\/fphar.2022.1076266"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"ofz297","DOI":"10.1093\/ofid\/ofz297","article-title":"Switching tenofovir\/emtricitabine\/efavirenz (TDF\/FTC\/EFV) to TDF\/FTC\/rilpivirine vs continuing TDF\/FTC\/EFV in HIV-infected patients with virological suppression: A randomized controlled trial","volume":"6","author":"Wiriyatanakorn","year":"2019","journal-title":"Open Forum Infect. Dis."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"949","DOI":"10.4102\/sajhivmed.v20i1.949","article-title":"Switching at low HIV-1 RNA into fixed dose combinations: TDF\/FTC\/RPV is non-inferior to TDF\/FTC\/EFV in first-line suppressed patients living with HIV","volume":"20","author":"Munderi","year":"2019","journal-title":"S. Afr. J. HIV Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1093\/jac\/dky547","article-title":"Tenofovir DF\/emtricitabine\/rilpivirine as HIV post-exposure prophylaxis: Results from a multicentre prospective study","volume":"74","author":"Chauveau","year":"2019","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1097\/QAD.0000000000002496","article-title":"The switch from tenofovir disoproxil fumarate to tenofovir alafenamide determines weight gain in patients on rilpivirine-based regimen","volume":"34","author":"Taramasso","year":"2020","journal-title":"AIDS"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1080\/14656566.2020.1713096","article-title":"Evaluating emtricitabine + rilpivirine + tenofovir alafenamide in combination for the treatment of HIV-infection","volume":"21","author":"Mu","year":"2020","journal-title":"Expert. Opin. Pharmacother."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e70275","DOI":"10.1002\/hsr2.70275","article-title":"Metabolic outcomes of changing from rilpivirine\/tenofovir disoproxil fumarate\/emtricitabine to rilpivirine\/tenofovir alafenamide\/emtricitabine: A longitudinal study","volume":"7","author":"Wu","year":"2024","journal-title":"Health Sci. Rep."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"10550","DOI":"10.1038\/s41467-024-54783-0","article-title":"SHIV remission in macaques with early treatment initiation and ultra long-lasting antiviral activity","volume":"15","author":"Daly","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Pasquau, J., de Jesus, S.E., Arazo, P., Crusells, M.J., R\u00edos, M.J., Lozano, F., de la Torre, J., Galindo, M.J., Carmena, J., and Santos, J. (2019). Effectiveness and safety of dual therapy with rilpivirine and boosted darunavir in treatment-experienced patients with advanced HIV infection: A preliminary 24 week analysis (RIDAR study). BMC Infect. Dis., 19.","DOI":"10.1186\/s12879-019-3817-6"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1093\/jac\/dkaa072","article-title":"Effectiveness of boosted darunavir plus rilpivirine in patients with long-lasting HIV-1 infection: DARIL study","volume":"75","author":"Navarro","year":"2020","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1080\/25787489.2020.1734752","article-title":"96-week results of a dual therapy with darunavir\/ritonavir plus rilpivirine once a day vs triple therapy in patients with suppressed viraemia: Virological success and non-HIV related morbidity evaluation","volume":"21","author":"Adorni","year":"2020","journal-title":"HIV Res. Clin. Pract."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1093\/jac\/dkaa018","article-title":"Rilpivirine plus cobicistat-boosted darunavir as a two-drug switch regimen in HIV-infected, virologically suppressed subjects on steady standard three-drug therapy: A randomized, controlled, non-inferiority trial (PROBE\u20092)","volume":"75","author":"Maggiolo","year":"2020","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s12981-020-00272-5","article-title":"Efficacy and safety of abacavir\/lamivudine plus rilpivirine as a first-line regimen in treatment-na\u00efve HIV-1 infected adults","volume":"17","author":"Ho","year":"2020","journal-title":"AIDS Res. Ther."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s12981-021-00402-7","article-title":"Safety and effectiveness of switching to Abacavir\/Lamivudine plus rilpivirine for maintenance therapy in virologically suppressed HIV-1 individuals in Singapore (SEALS)","volume":"18","author":"Lim","year":"2021","journal-title":"AIDS Res. Ther."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1080\/15284336.2019.1628460","article-title":"Dolutegravir plus rilpivirine as dual regimen in virologically suppressed HIV-1 infected patients in a clinical setting","volume":"20","author":"Casado","year":"2019","journal-title":"HIV Res. Clin. Pract."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1177\/1060028019831674","article-title":"Dolutegravir-rilpivirine, dual antiretroviral therapy for the treatment of HIV-1 infection","volume":"53","author":"Hester","year":"2019","journal-title":"Ann. Pharmacother."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"e576","DOI":"10.1016\/S2352-3018(19)30149-3","article-title":"Efficacy and safety of dolutegravir-rilpivirine for maintenance of virological suppression in adults with HIV-1: 100-week data from the randomised, open-label, phase 3 SWORD-1 and SWORD-2 studies","volume":"6","author":"Aboud","year":"2019","journal-title":"Lancet HIV"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"825","DOI":"10.4102\/sajhivmed.v20i1.825","article-title":"The role of rilpivirine in Southern Africa","volume":"20","author":"Moorhouse","year":"2019","journal-title":"S. Afr. J. HIV Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1097\/QAI.0000000000002449","article-title":"Brief report: Durable suppression and low rate of virologic failure 3 years after switch to dolutegravir +rilpivirine 2-drug regimen: 148-week results from the SWORD-1 and SWORD-2 randomized clinical trials","volume":"85","author":"Orkin","year":"2020","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1111\/bcp.15683","article-title":"Pharmacokinetic and pharmacokinetic\/pharmacodynamic characterization of the dolutegravir\/rilpivirine two-drug regimen in SWORD-1\/-2 phase 3 studies","volume":"89","author":"Mehta","year":"2023","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Hidalgo-Tenorio, C., Vinuesa, D., Garc\u00eda-Vallecillos, C., Mu\u00f1oz-Medina, L., Sequera, S., Javier, R., L\u00f3pez-Ruz, M., Sadyrbaeva-Dolgova, S., and Pasquau, J. (2022). Rildo: Real-world multicenter study on the effectiveness and safety of single-tablet regimen of dolutegravir plus rilpivirine in treatment-experienced people living with HIV. Viruses, 14.","DOI":"10.3390\/v14122626"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1111\/hiv.13489","article-title":"Efficacy and safety of dolutegravir\/rilpivirine in real-world clinical practice. GeSIDA study 1119","volume":"24","author":"Palacios","year":"2023","journal-title":"HIV Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"e29252","DOI":"10.1097\/MD.0000000000029252","article-title":"Dolutegravir plus rilpivirine: Benefits beyond viral suppression: DORIPEX retrospective study","volume":"101","author":"Troya","year":"2022","journal-title":"Medicine"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/QAI.0000000000003019","article-title":"Brief report: Evaluation of inflammation and atherogenesis biomarkers through 148 weeks postswitch to dolutegravir and rilpivirine in SWORD-1\/SWORD-2","volume":"91","author":"Llibre","year":"2022","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Due\u00f1as-Guti\u00e9rrez, C., Buz\u00f3n, L., Pedrero-Tom\u00e9, R., Iribarren, J.A., De Los Santos, I., De la Fuente, S., Pousada, G., Moran, M.A., Moreno, E., and Ferreira, E. (2023). Efficacy and safety of two-drug regimens with dolutegravir plus rilpivirine or lamivudine in HIV-1 virologically suppressed people living with HIV. Viruses, 15.","DOI":"10.3390\/v15040936"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1093\/jac\/dkac362","article-title":"Analysing the efficacy and tolerability of dolutegravir plus either rilpivirine or lamivudine in a multicentre cohort of virologically suppressed PLWHIV","volume":"78","author":"Ciccullo","year":"2022","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1111\/bcp.15890","article-title":"Therapeutic drug monitoring and virological response at week 48 in a cohort of HIV-1-infected patients switching to dolutegravir\/rilpivirine dual maintenance therapy (ANRS-MIE-BIRIDER study)","volume":"90","author":"Lemaitre","year":"2024","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1111\/hiv.13617","article-title":"Sex differences in the effectiveness and tolerability of dolutegravir plus rilpivirine as a switch strategy in people living with HIV","volume":"25","author":"Mican","year":"2024","journal-title":"HIV Med."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1007\/s40121-024-00961-y","article-title":"Two-drug regimens dolutegravir\/lamivudine and dolutegravir\/rilpivirine are effective with few discontinuations in US real-world settings: Results from the TANDEM study","volume":"13","author":"Schneider","year":"2024","journal-title":"Infect. Dis. Ther."},{"key":"ref_53","first-page":"179","article-title":"Evaluating cabotegravir\/rilpivirine long-acting, injectable in the treatment of HIV infection: Emerging data and therapeutic potential","volume":"11","author":"Fernandez","year":"2019","journal-title":"HIV AIDS"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1093\/infdis\/jiy726","article-title":"Predicting drug-drug interactions between rifampicin and long-acting cabotegravir and rilpivirine using physiologically based pharmacokinetic modeling","volume":"219","author":"Rajoli","year":"2019","journal-title":"J. Infect. Dis."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1056\/NEJMoa1904398","article-title":"Long-acting cabotegravir and rilpivirine for maintenance of HIV-1 suppression","volume":"382","author":"Swindells","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1056\/NEJMoa1909512","article-title":"Long-acting cabotegravir and rilpivirine after oral induction for HIV-1 infection","volume":"382","author":"Orkin","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1056\/NEJMe2002199","article-title":"Monthly injectable antiretroviral therapy\u2014Version 1.0 of a new treatment approach","volume":"382","author":"Currier","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"3533","DOI":"10.1007\/s10461-020-02929-8","article-title":"Patient-reported outcomes in ATLAS and FLAIR participants on long-acting regimens of cabotegravir and rilpivirine over 48 weeks","volume":"24","author":"Murray","year":"2020","journal-title":"AIDS Behav."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1097\/QAI.0000000000002466","article-title":"Long-acting injectable cabotegravir + rilpivirine for HIV maintenance therapy: Week 48 pooled analysis of phase 3 ATLAS and FLAIR trials","volume":"85","author":"Rizzardini","year":"2020","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1007\/s40265-020-01326-8","article-title":"Cabotegravir plus rilpivirine: First approval","volume":"80","author":"Markham","year":"2020","journal-title":"Drugs"},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"(2021). Cabotegravir and Rilpivirine. Am. J. Health Syst. Pharm., 78, 925\u2013931.","DOI":"10.1093\/ajhp\/zxab088"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1093\/jac\/dkz504","article-title":"Pharmacokinetics and antiviral activity of cabotegravir and rilpivirine in cerebrospinal fluid following long-acting injectable administration in HIV-infected adults","volume":"75","author":"Letendre","year":"2020","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1097\/QAD.0000000000002883","article-title":"Exploring predictors of HIV-1 virologic failure to long-acting cabotegravir and rilpivirine: A multivariable analysis","volume":"35","author":"Cutrell","year":"2021","journal-title":"AIDS"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1177\/1060028021995586","article-title":"Cabotegravir-rilpivirine: The first complete long-acting injectable regimen for the treatment of HIV-1 infection","volume":"55","author":"Durham","year":"2021","journal-title":"Ann. Pharmacother."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1097\/QAD.0000000000003085","article-title":"Long-acting cabotegravir and rilpivirine for HIV-1 suppression: Switch to 2-monthly dosing after 5 years of daily oral therapy","volume":"36","author":"Mills","year":"2022","journal-title":"AIDS"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"e185","DOI":"10.1016\/S2352-3018(20)30340-4","article-title":"Long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection: 96-week results of the randomised, open-label, phase 3 FLAIR study","volume":"8","author":"Orkin","year":"2021","journal-title":"Lancet HIV"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"e679","DOI":"10.1016\/S2352-3018(21)00185-5","article-title":"Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 96-week results: A randomised, multicentre, open-label, phase 3b, non-inferiority study","volume":"8","author":"Jaeger","year":"2021","journal-title":"Lancet HIV"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1007\/s40262-021-01005-1","article-title":"Pharmacokinetics and drug-drug interactions of long-acting intramuscular cabotegravir and rilpivirine","volume":"60","author":"Hodge","year":"2021","journal-title":"Clin. Pharmacokinet."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1358\/dot.2022.58.12.3448340","article-title":"Cabotegravir: A novel HIV integrase inhibitor combined with rilpivirine as the first long-acting injectable program for the treatment of HIV infection","volume":"58","author":"Zeuli","year":"2022","journal-title":"Drugs Today"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1097\/COH.0000000000000708","article-title":"A new paradigm for antiretroviral delivery: Long-acting cabotegravir and rilpivirine for the treatment and prevention of HIV","volume":"17","author":"Bares","year":"2022","journal-title":"Curr. Opin. HIV AIDS"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"106627","DOI":"10.1016\/j.ijantimicag.2022.106627","article-title":"The future of long-acting cabotegravir plus rilpivirine therapy: Deeds and misconceptions","volume":"60","author":"Rusconi","year":"2022","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1097\/QAD.0000000000003505","article-title":"Impact of rilpivirine cross-resistance on long-acting cabotegravir-rilpivirine in low and middle-income countries","volume":"37","author":"Steegen","year":"2023","journal-title":"AIDS"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"e0170221","DOI":"10.1128\/aac.01702-21","article-title":"Impact of Integrase Sequences from HIV-1 Subtypes A6\/A1 on the In Vitro Potency of Cabotegravir or Rilpivirine","volume":"66","author":"Jeffrey","year":"2022","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1093\/jac\/dkad258","article-title":"Archived rilpivirine-associated resistance mutations among ART-naive and virologically suppressed people living with HIV-1 subtype C in Botswana: Implications for cabotegravir\/rilpivirine use","volume":"78","author":"Maruapula","year":"2023","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1097\/QAD.0000000000003590","article-title":"HIV virologic response and baseline genotypic resistance in a long-acting cabotegravir\/rilpivirine initiation program","volume":"37","author":"Masich","year":"2023","journal-title":"AIDS"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1093\/cid\/ciad020","article-title":"Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with human immunodeficiency virus 1 type 1 infection: 152-week results from ATLAS-2M, a randomized, open-label, phase 3b, noninferiority study","volume":"76","author":"Overton","year":"2023","journal-title":"Clin. Infect. Dis."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1080\/14656566.2022.2126310","article-title":"An evaluation of long-acting cabotegravir + rilpivirine for the treatment of virologically suppressed adults living with HIV","volume":"23","author":"Qazzaz","year":"2022","journal-title":"Expert. Opin. Pharmacother."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"e14","DOI":"10.1097\/QAI.0000000000003142","article-title":"Transient viremia in young adults with HIV after the switch to long-acting cabotegravir and rilpivirine: Considerations for dosing schedule and monitoring","volume":"92","author":"Rakhmanina","year":"2023","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1111\/hiv.13439","article-title":"Pregnancy outcomes and pharmacokinetics in pregnant women living with HIV exposed to long-acting cabotegravir and rilpivirine in clinical trials","volume":"24","author":"Patel","year":"2023","journal-title":"HIV Med."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1007\/s11095-022-03408-6","article-title":"Development and evaluation of dissolving microarray patches for co-administered and repeated intradermal delivery of long-acting rilpivirine and cabotegravir nanosuspensions for paediatric HIV antiretroviral therapy","volume":"40","author":"Moffatt","year":"2023","journal-title":"Pharm. Res."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1093\/cid\/ciac901","article-title":"Management of drug-drug interactions between long-acting cabotegravir and rilpivirine and comedications with inducing properties: A modeling study","volume":"76","author":"Bettonte","year":"2023","journal-title":"Clin. Infect. Dis."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1093\/cid\/ciad024","article-title":"Long-acting cabotegravir and rilpivirine: Innovation, new challenges, and opportunities","volume":"76","author":"Llibre","year":"2023","journal-title":"Clin. Infect. Dis."},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Parker, B., Ward, T., Hayward, O., Jacob, I., Arthurs, E., Becker, D., Anderson, S.J., Chounta, V., and Van de Velde, N. (2021). Cost-effectiveness of the long-acting regimen cabotegravir plus rilpivirine for the treatment of HIV-1 and its potential impact on adherence and viral transmission: A modelling study. PLoS ONE, 16.","DOI":"10.1371\/journal.pone.0245955"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1007\/s40121-023-00840-y","article-title":"Cabotegravir and rilpivirine long-acting antiretroviral therapy administered every 2 months is cost-effective for the treatment of HIV-1 in Spain","volume":"12","author":"Moreno","year":"2023","journal-title":"Infect. Dis. Ther."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"e332","DOI":"10.1016\/S2352-3018(23)00051-6","article-title":"Long-acting antiretrovirals and HIV treatment adherence","volume":"10","author":"Nachega","year":"2023","journal-title":"Lancet HIV"},{"key":"ref_86","first-page":"20499361231214626","article-title":"Practical dosing guidance for the management of clinician-administered injections of long-acting cabotegravir and rilpivirine","volume":"10","author":"Patel","year":"2023","journal-title":"Ther. Adv. Infect. Dis."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1093\/cid\/ciae523","article-title":"Perspectives of people with HIV on implementing long acting cabotegravir plus rilpivirine in clinics and community settings in the UK: Results from the anti-sexist, anti-racist, anti-ageist ILANA study","volume":"80","author":"Orkin","year":"2025","journal-title":"Clin. Infect. Dis."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1093\/cid\/ciae500","article-title":"48-week viral suppression rates in people with HIV starting long-acting CAB\/RPV with initial viremia","volume":"80","author":"Hickey","year":"2025","journal-title":"Clin. Infect. Dis."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"2932","DOI":"10.1093\/jac\/dkae308","article-title":"Real-world data on long-acting intramuscular maintenance therapy with cabotegravir and rilpivirine mirror Phase 3 results","volume":"79","author":"Serris","year":"2024","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"Davis, J.M., Rana, A., Sax, P.E., and Bares, S.H. (Clin. Infect. Dis., 2024). Long-acting cabotegravir plus rilpivirine in people with HIV with adherence challenges and viremia: Current data and future directions, Clin. Infect. Dis., online ahead of print.","DOI":"10.1093\/cid\/ciae557"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1097\/QAD.0000000000003984","article-title":"CD4+\/CD8+ improvement after switch from a second-generation integrase inhibitor regimen to long-acting cabotegravir and rilpivirine","volume":"38","author":"Muccini","year":"2024","journal-title":"AIDS"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1093\/cid\/ciae472","article-title":"Comparison of at-home versus in-clinic receipt of long-acting injectable cabotegravir\/rilpivirine","volume":"80","author":"Kirk","year":"2025","journal-title":"Clin. Infect. Dis."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"e0078123","DOI":"10.1128\/aac.00781-23","article-title":"Pharmacokinetics and tolerability of cabotegravir and rilpivirine long-acting intramuscular injections to the vastus lateralis (lateral thigh) muscles of healthy adult participants","volume":"68","author":"Han","year":"2024","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"e0017524","DOI":"10.1128\/aac.00175-24","article-title":"Switching to deltoid intramuscular injections maintains therapeutic trough concentrations of rilpivirine and cabotegravir in people with HIV","volume":"68","author":"Cossu","year":"2024","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Maguire, C., Rueve, K., Farmer, E., Huesgen, E., Karaj, A., Binkley, A., Mounzer, K., Brizzi, M., Chary, P., and Sung, P. (Clin. Infect. Dis., 2024). Real world virologic outcomes in patients with elevated body mass index receiving long acting cabotegravir\/rilpivirine, Clin. Infect. Dis., online ahead of print.","DOI":"10.1093\/cid\/ciae579"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"e34","DOI":"10.1093\/infdis\/jiad580","article-title":"Efficacy, safety, and pharmacokinetics by body mass index category in phase 3\/3b long-acting cabotegravir plus rilpivirine trials","volume":"230","author":"Elliot","year":"2024","journal-title":"J. Infect. Dis."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"e211","DOI":"10.1016\/S2352-3018(23)00300-4","article-title":"Safety and pharmacokinetics of oral and long-acting injectable cabotegravir or long-acting injectable rilpivirine in virologically suppressed adolescents with HIV (IMPAACT 2017\/MOCHA): A phase 1\/2, multicentre, open-label, non-comparative, dose-finding study","volume":"11","author":"Gaur","year":"2024","journal-title":"Lancet HIV"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1093\/cid\/ciae331","article-title":"Interest in and preference for long-acting injectable antiretroviral therapy in the era of approved cabotegravir\/rilpivirine among reproductive-aged women in the U.S. south","volume":"80","author":"Collins","year":"2025","journal-title":"Clin. Infect. Dis."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"e26243","DOI":"10.1002\/jia2.26243","article-title":"Implementation of long-acting cabotegravir and rilpivirine: Primary results from the perspective of staff study participants in the Cabotegravir and Rilpivirine Implementation Study in European Locations","volume":"27","author":"Gutner","year":"2024","journal-title":"J. Int. AIDS Soc."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1097\/QAI.0000000000003421","article-title":"Identifying implementation determinants and strategies for long-acting injectable cabotegravir-rilpivirine in people with HIV who are virally unsuppressed","volume":"96","author":"Hickey","year":"2024","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1093\/cid\/ciae016","article-title":"Virological failure after switch to long-acting cabotegravir and rilpivirine injectable therapy: An in-depth analysis","volume":"79","author":"Gisolf","year":"2024","journal-title":"Clin. Infect. Dis."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1111\/hiv.13679","article-title":"Multicentre service evaluation of injectable cabotegravir and rilpivirine delivery and outcomes across 12 UK clinics (SHARE LAI-net)","volume":"25","author":"Ring","year":"2024","journal-title":"HIV Med."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/S1473-3099(24)00289-5","article-title":"Switch to long-acting cabotegravir and rilpivirine in virologically suppressed adults with HIV in Africa (CARES): Week 48 results from a randomised, multicentre, open-label, non-inferiority trial","volume":"24","author":"Kityo","year":"2024","journal-title":"Lancet Infect. Dis."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1016\/S1473-3099(24)00296-2","article-title":"Implementing long-acting injectable cabotegravir and rilpivirine in Africa","volume":"24","author":"Orkin","year":"2024","journal-title":"Lancet Infect. Dis."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1097\/QAI.0000000000003448","article-title":"Safety and effectiveness from the cabotegravir and rilpivirine implementation study in European locations study: Phase 3b hybrid type III implementation study integrating cabotegravir + rilpivirine long-acting into European clinical settings","volume":"96","author":"Ghosn","year":"2024","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1097\/QAI.0000000000003500","article-title":"Acceptability of long-acting cabotegravir + rilpivirine in a large, urban, ambulatory HIV clinic","volume":"97","author":"Luc","year":"2024","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1097\/COH.0000000000000897","article-title":"Long-acting antiretroviral therapy in the context of viral suppression","volume":"20","author":"Ring","year":"2025","journal-title":"Curr. Opin. HIV AIDS"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/COH.0000000000000904","article-title":"Use of long-acting injectable cabotegravir\/rilpivirine in people with HIV and adherence challenges","volume":"20","author":"Christopoulos","year":"2025","journal-title":"Curr. Opin. HIV AIDS"}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/17\/7\/959\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:06:25Z","timestamp":1760033185000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/17\/7\/959"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,8]]},"references-count":108,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,7]]}},"alternative-id":["v17070959"],"URL":"https:\/\/doi.org\/10.3390\/v17070959","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,8]]}}}